Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 10471076
Compositions and methods to treat vision disorders
granted -
US 10471109
Compositions and methods for promoting nitric oxide production through an oral delivery system
granted -
US 10463684
Nucleobase analogue derivatives and their applications
granted -
US 10464941
Therapeutic compounds
granted -
US 10464983
Variants of adrenomedullin and calcitonin gene-related peptide and methods of use
granted -
US 10465227
Microbial testing devices, methods of making microbial testing devices and methods of identifying novel antimicrobial drug candidates
granted -
US 10464994
Recombinant clusterin and use thereof in the treatment and prevention of disease
granted -
US 10464989
Polypeptides, cells, and methods involving engineered CD16
granted -
US 10463685
Telomerase mediated telomere altering compounds
granted -
US 10463734
Nanoparticle therapy in cancer
granted -
US 10457676
Capsazepine analogs for the treatment of cancer and other proliferative diseases
granted -
US 10456346
Cosmetic formulations for topical applications containing erythropoietin-derived molecules
granted -
US 10457662
Substituted amides for treating and preventing cancer
granted -
US 10456448
PTD-SMAD7 therapeutics
granted -
US 10450355
Lectins and uses thereof
granted -
US 10450352
Engineered polypeptides for antigen delivery
granted -
US 10450384
Compositions of alpha-1 antitrypsin fusion molecules
granted -
US 10449254
Ionic liquids for transdermal drug delivery
granted -
US 10449321
Gas delivery devices
granted -
US 10449241
Interferon-Ξ² production modulating Listeria strains and methods for using same
granted -
US 10450275
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
granted -
US 10449182
Sorafenib derivatives as p21 inhibitors
granted -
US 10449207
Acyclic nucleoside phosphonate diesters
granted -
US 10450572
Androgen receptor variant inhibitors and methods of using
granted -
US 10448637
Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same
granted -
US 10449230
Polymyxin derived cell penetrating scaffolds
granted -
US 10451610
Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1
granted -
US 10449232
Puma protein expression vector and use thereof in gene therapy
granted -
US 10448634
Composition with high antimicrobial activity and low toxicity
granted -
US 10443076
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10442911
Dendritic macroporous hydrogels prepared by crystal templating
granted -
US 10442182
In vivo live 3D printing of regenerative bone healing scaffolds for rapid fracture healing
granted -
US 10441644
H3.3 CTL peptides and uses thereof
granted -
US 10441607
Multifunctional linker technology containing an N4 group
granted -
US 10442852
Methods and compositions for treatment of symptoms associated with intracranial hemorrhage
granted -
US 10441586
CRMP2 SUMOylation inhibitors and uses thereof
granted -
US 10435355
Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments
granted -
US 10435435
Quinstatin compounds
granted -
US 10434069
Protease assisted native-protein delivery approach (PANDA)
granted -
US 10434063
Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
granted -
US 10434075
FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer
granted -
US 10434111
Compositions and methods for modification of biomolecules
granted -
US 10434134
Peptide treatment for inflammation and fibrosis
granted -
US 10434062
Compositions and methods of making brittle-matrix particles through blister pack freezing
granted -
US 10434078
GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
granted -
US 10428352
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10428113
Compositions for expanding regulatory T cells (Treg), and treating autoimmune and inflammatory diseases and conditions
granted -
US 10428143
Modulation of stimulatory and non-stimulatory myeloid cells
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory